Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma

Main Article Content

Georgina V Long
Axel Hauschild
Mario Santinami
Victoria Atkinson
Mario Mandala
Vanna Chiarion-Sileni
James Larkin
Marta Nyakas
Caroline Dutriaux
Andrew Haydon
Caroline Robert
Laurent Mortier
Jacob Schachter
Dirk Schadendorf
Thierry Lesimple
Ruth Plummer
Ran Ji
Pingkuan Zhang
Bijoyesh Mookerjee
Jeff Legos
Richard Kefford
Reinhard Drummer
John M Kirkwood


melanoma, genetics, dabrafenib, trametinib


Abstract not available.


Disclosures: Study sponsored by Novartis.


Copyright 2018 SKIN

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)